Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 16/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3520902 | 0.91 | FFAR1 (0.61) | FFAR1MRGPRX4PPARDGPR34RXRA | |
| SCHEMBL13118134 | 0.91 | FFAR1 (0.52) | FFAR1MRGPRX4PPARDGPR34RXRA | |
| SCHEMBL13118136 | 0.91 | FFAR1 (0.50) | FFAR1MRGPRX4PPARDRXRANR1H2 | |
| SCHEMBL13118139 | 0.90 | FFAR1 (0.49) | FFAR1MRGPRX4PPARDRXRANR1H2 | |
| SCHEMBL13548833 | 0.88 | FFAR1 (0.47) | FFAR1MRGPRX4PPARDGPR34RXRA | |
| SCHEMBL13118141 | 0.88 | FFAR1 (0.48) | FFAR1MRGPRX4PPARDRXRANR1H2 | |
| SCHEMBL3523470 | 0.81 | FFAR1 (0.66) | FFAR1MRGPRX4PPARDGPR34RXRA | |
| SCHEMBL3520170 | 0.81 | FFAR1 (0.62) | FFAR1MRGPRX4PPARDRXRANR1H2 | |
| SCHEMBL3519034 | 0.79 | FFAR1 (0.60) | FFAR1MRGPRX4PPARDRXRANR1H2 | |
| SCHEMBL3524634 | 0.79 | FFAR1 (0.60) | FFAR1MRGPRX4PPARDRXRANR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816367-B2 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7649110-B2 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | PNLIP, IAPP, GPR119 | FFAR1 1245/4885MRGPRX4 713/4885PPARD 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.